雷珠单抗对糖尿病视网膜病变患者手术前后血清VE-cadherin和bFGF的影响

doi:10.3969/j.issn.1006-6233.2020.08.002

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1200 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effects of razumab on serum vascular endothelial cadherin (VE-cadherin) and basic fibroblast growth factor (bFGF) in patients with diabetic retinopathy during vitrectomy. Methods: 85 patients with diabetic retinopathy admitted to our hospital from March 2018 to May 2019 were randomly divided into two groups, 43 cases in study group and 42 cases in control group. The control group received vitrectomy, while the study group received intravitreal injection of razumab on the basis of the control group. The operation condition, visual acuity improvement and levels of serum vascular endothelial growth factor (VEGF), bFGF and VE-cadherin were observed in the two groups, and the complications were evaluated. Results: The operation time and intraoperative bleeding volume in the study group were significantly less than those in the control group (P<0.05). The macular fovea retinal thickness was significantly smaller than that in the control group (P<0.05). The visual acuity improvement rate was significantly higher than that of the control group (83.72 % VS 57.14 %, P<0.05). After treatment, the levels of serum VEGF, bFGF and VE-cadherin in the two groups were lower than those before treatment (P<0.05), and the levels of serum VEGF, bFGF and VE-cadherin in the study group were significantly lower than those in the control group (P<0.05). In addition, the incidence of postoperative complications in the study group was 6.98%, which was significantly lower than 23.81% in the control group (P<0.05). Conclusion: The intravitreal injection of rapunzumab before operation can optimize the operation environment, reduce the risk of operation, effectively improve vision and reduce postoperative complications. The clinical effect is significant and worthy of promotion.

Key words： Diabetic retinopathy Razumab Vitrectomy VE cadherin BFGF(Basic fibroblast growth factor)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Wenjuan
	JI Fengtao
	LI Yongrong

Cite this article:

SUN Wenjuan,JI Fengtao,LI Yongrong. Effects of Razumab on Serum VE-Cadherin and bFGF in Diabetic Retinopathy Patients Before and After Operation[J]. HeBei Med, 2020, 26(8): 1237-1240.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.08.002 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I8/1237

[1] Ji B, Wei H, Ding Y, et al. Protective potential of klotho protein on diabetic retinopathy: evidence from clinical and vitro studies[J].Diabetes Invest, 2020, 11(1):162~169.
[2] Liu E, Estevez JJ, Kaidonis G, et al. Long-term survival rates of patients undergoing vitrectomy for diabetic retinopathy in an Australian population: a population-based audit-Response[J]. Clin Exp Ophthalmol, 2019, 47(6):817~818.
[3] 高韶晖, 裴晗, 赵朝霞, 等.增生型糖尿病视网膜病变患眼玻璃体切割手术未联合眼内填充治疗后玻璃体积血的危险因素分析[J].中华眼底病杂志, 2019, 35(2):135~139.
[4] 刘爱琴, 宋子宣, 吴娟, 等.雷珠单抗辅助玻璃体视网膜手术治疗增生型糖尿病视网膜病变[J].眼科新进展, 2019, 39(6):574~578.
[5] 中华医学会糖尿病学分会视网膜病变学组.糖尿病视网膜病变防治专家共识[J].中华糖尿病杂志, 2018, 10(4):241~247.
[6] Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care:the international council of ophthalmology recommendations for screening, follow-up, referral and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10):1608~1622.
[7] 张妍春, 任秀瑜, 康紫薇, 等.玻璃体切除术联合雷珠单抗玻璃体注射治疗增殖性糖尿病视网膜病变的临床研究[J].海南医学, 2018, 29(23):3296~3299.
[8] 黄玲, 徐金华, 林琳.雷珠单抗辅助微创玻璃体切割术治疗严重PDR的临床研究[J].国际眼科杂志, 2018, 18(8):1511~1514.
[9] 李鑫, 陈毕锋, 胡庆华, 等.雷珠单抗玻璃体腔注射联合Ahmed青光眼阀植入及全视网膜光凝治疗新生血管性青光眼[J].临床眼科杂志, 2018, 26(3):221~223.
[10] 闫配, 张晓红, 张莉, 等.玻璃体腔注射雷珠单抗联合沃丽汀治疗增殖性糖尿病视网膜病变出血的疗效及对视力、内皮生长因子的影响[J].药物生物技术, 2019, 26(2):127~130.
[11] 刘辉, 孙静淳.玻璃体腔内注射雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼[J].中国临床研究, 2019, 32(8):1059~1062.
[12] Georgalas I, Tservakis I, Kiskira E, et al. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: A 12-month prospective study[J]. Cutan Ocul Toxicol, 2019, 38(4):330~337.
[13] Sui A, Zhong Y, Demetriades AM, et al. Inhibition of integrin α5β1 ameliorates VEGF-induced retinal neovascularization and leakage by suppressing NLRP3 inflammasome signaling in a mouse model[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(5):951~961.
[14] Deng H, Wang S, Wang X, et al. Puerarin protects against LPS-induced vascular endothelial cell hyperpermeability via preventing downregulation of endothelial cadherin[J]. Inflammation, 2019, 42(1):1504~1510.